Aspergillus Fumigatus (Asp f 1) IgE Test · Blood

If you have asthma that keeps worsening, recurring chest infections, or a positive but ambiguous mold allergy result, this test answers a specific question: is your body actually reacting to Aspergillus fumigatus, or is it cross-reacting to something else that looks similar to your immune system? The answer changes what you watch for, what you do, and how aggressively you investigate further lung disease.

Asp f 1 (Aspergillus fumigatus allergen 1) is a major, species-specific protein released by the fungus when it grows. Measuring IgE (immunoglobulin E, the antibody class behind allergic reactions) against this single protein is more targeted than the older whole-extract mold tests, which can light up positive simply because you're allergic to a different fungus.

Why This Test Exists

Standard Aspergillus IgE tests use a crude extract of the whole fungus. That extract contains dozens of proteins, some of which are shared with other molds. So a positive result can mean genuine Aspergillus sensitization, or it can mean your immune system is reacting to a protein that happens to be present in Aspergillus but is actually driving allergy from another mold entirely.

Asp f 1 is largely unique to Aspergillus fumigatus. A positive IgE result against this specific protein indicates true sensitization to this fungus, not a look-alike. In one study of asthmatics, switching from crude extract testing to recombinant Asp f 1 and Asp f 2 testing reclassified people previously labeled as Aspergillus-sensitized as not actually allergic to it. That changes the entire diagnostic picture.

Allergic Bronchopulmonary Aspergillosis (ABPA)

ABPA is the disease this test is most useful for ruling in or out. It's an aggressive allergic reaction to Aspergillus growing in the airways, mostly affecting people with asthma or cystic fibrosis. Left undiagnosed, it can cause bronchiectasis (permanent widening and scarring of the airways) and progressive loss of lung function.

In Japanese and Chinese cohorts, IgE to Asp f 1 and Asp f 2 was significantly higher in people with ABPA than in people who were sensitized to Aspergillus but didn't have ABPA. Positivity to these components improved the ability to distinguish ABPA from simple sensitization, with diagnostic ROC AUC values of 0.75 to 0.78. In a meta-analysis combining studies of asthmatics, IgE to combinations including Asp f 1 reached a pooled sensitivity of roughly 97% for ABPA. International ABPA guidelines from the ISHAM working group state that IgE to recombinant Asp f 1 and Asp f 2 is highly specific and useful for distinguishing ABPA from other fungal conditions.

Asthma With Reduced Lung Function

Even without ABPA, sensitization to Aspergillus fumigatus is associated with worse asthma. A study of 93 asthmatics found that IgE sensitization to Aspergillus was linked to reduced lung function and more fixed airflow obstruction, the kind that doesn't fully reverse with a rescue inhaler. In children, Aspergillus-sensitized asthma showed higher severity, higher total IgE, more eosinophils, and worse FEV1 (forced expiratory volume in 1 second, a standard breathing test) than asthma without this sensitization.

Knowing whether you carry true Aspergillus sensitization, versus a misleading positive from cross-reactivity, helps explain why your asthma may be acting differently from what your inhaler regimen can control.

Cystic Fibrosis and Chronic Lung Disease

In people with cystic fibrosis, Asp f 1 IgE participates in classifying whether Aspergillus is simply present in the airway (colonization), driving allergic inflammation (sensitization), or causing ABPA. These phenotypes carry different prognoses and need different management. In a community study of over 16,000 people in North India with COPD (chronic obstructive pulmonary disease), about 18% had Aspergillus sensitization and roughly 7% had ABPA. Sensitized people had lower predicted FEV1 than those without sensitization.

Prognosis After Diagnosis

Higher baseline Aspergillus fumigatus-specific IgE at the time of ABPA diagnosis predicts higher risk of exacerbation. In a study of 149 ABPA patients, levels above 9.88 kUA/L at diagnosis were associated with increased risk of flare-ups over the following year. This is a related but different measurement from Asp f 1-specific IgE specifically, since most prognosis data comes from whole-extract testing rather than component testing. Whether Asp f 1-specific IgE carries the same prognostic weight has not been directly established.

Why a Negative Result Still Matters

A low or negative Asp f 1 IgE, in someone who tested positive on a crude Aspergillus extract, often means the positive came from cross-reactivity with other fungi, not true Aspergillus disease. In ABPA-like syndromes, a low Asp f 1 IgE can also point toward allergic bronchopulmonary mycosis driven by a different fungus, such as Aspergillus flavus or others. This shifts the search for the actual trigger.

Reconciling Confusing Results

It's possible to have a strong positive whole-extract Aspergillus IgE result alongside a low Asp f 1 IgE. This isn't a contradiction. The crude extract contains many proteins, some shared with other molds. Your immune system may be reacting to one of those shared proteins from a completely different fungal exposure. The component test is the more reliable read on whether Aspergillus fumigatus itself is the problem. Treat the component result as the truer signal.

When Results Can Be Misleading

• Atopic dermatitis: people with comorbid eczema can show elevated low-level IgE to multiple Aspergillus components, including some that resemble a true ABPA pattern. Your dermatologic history matters when interpreting a panel of component results.
• Component cross-reactivity: Asp f 1 is largely species-specific, but related allergens like Asp f 3 and Asp f 6 can show cross-reactivity with other fungi. A full component panel rather than Asp f 1 alone usually gives the clearest picture.
• Cross-sensitization to other molds: positive crude Aspergillus IgE with negative Asp f 1 and Asp f 2 typically reflects allergy to a different fungus that shares some proteins with Aspergillus.
• Assay variability: different labs use different cutoffs and methods. Track your levels at the same lab when comparing results over time.

Tracking Your Trend

For people with ABPA or Aspergillus-sensitized asthma, the most useful blood marker for monitoring disease activity is total IgE, not Asp f 1-specific IgE. In a study of 81 ABPA patients treated with steroids for 8 weeks, median total IgE fell by 51.9%, while Aspergillus fumigatus-specific IgE changed minimally on average. During documented exacerbations, total IgE rose by more than 50% in 92.3% of episodes, but Aspergillus-specific IgE rose in only 38.5%.

Use Asp f 1 IgE for initial diagnosis and characterization. Use total IgE, eosinophil count, and imaging for follow-up. Once you have a baseline Asp f 1 IgE result, retesting it makes sense if your clinical picture changes substantially, if you're being evaluated for a new diagnosis, or every one to two years to confirm sensitization status. Aggressive retesting of this specific marker has limited value because levels tend to be stable over treatment.

What an Unexpected Result Should Make You Do

If your Asp f 1 IgE comes back elevated, the next step is not panic. It's a structured workup. Pair the result with total IgE, eosinophil count, and Aspergillus-specific IgG. Get a chest CT if you have respiratory symptoms, recurrent infections, or significant asthma. If multiple of these findings line up, schedule a pulmonologist or allergist visit, and ask specifically about ABPA criteria. If you have cystic fibrosis or known bronchiectasis, the threshold for specialist involvement is lower.

If your Asp f 1 IgE is negative but a previous Aspergillus extract test was positive, the workup pivots. The relevant question becomes: which other fungus is actually driving your reaction? A broader fungal IgE panel and review of environmental exposures becomes more useful than continuing to chase Aspergillus.